Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $7.51 Analyst target: $43.09 Upside: 473.77%
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.